Cargando…

COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation

‘Renaissance took place in Chaos and plague’. It was COVID-19 pandemic, when world realized ayurveda co-interventions are praiseworthy even in acute, infective and fatal conditions like COVID-19. We report perhaps first case of COVID-19 patient with cancer managed with poly-herbal ayurvedic formulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dilip Pandkar, Prasad, Deshmukh, Santosh Raosaheb, Sachdeva, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372187/
https://www.ncbi.nlm.nih.gov/pubmed/35975131
http://dx.doi.org/10.1016/j.jaim.2022.100632
_version_ 1784767325233217536
author Dilip Pandkar, Prasad
Deshmukh, Santosh Raosaheb
Sachdeva, Vinay
author_facet Dilip Pandkar, Prasad
Deshmukh, Santosh Raosaheb
Sachdeva, Vinay
author_sort Dilip Pandkar, Prasad
collection PubMed
description ‘Renaissance took place in Chaos and plague’. It was COVID-19 pandemic, when world realized ayurveda co-interventions are praiseworthy even in acute, infective and fatal conditions like COVID-19. We report perhaps first case of COVID-19 patient with cancer managed with poly-herbal ayurvedic formulation and integrated approach. In the first wave of COVID-19 (June 2020), a 47 year old male with history of Chronic kidney disease and active B Cell Lymphoma complained of fever, malaise, cattarah and ageusia. He was found positive on RT-PCR which was done promptly and was later treated in home quarantine with antipyretics, Vitamin C and Madhav rasayan a polyherbal preparation containing Piper longum, Glycyrrhiza glabra, Eclipta alba, Achyranthes aspera, Embelia ribes and Aloe vera designed to modulate host response. It was challenging to treat a patient with cancer with immunocompromised status as he had recently finished his chemotherapy cycle (R–CHOP regimen). Patient well tolerated the intervention and recovered symptomatically. He did not developed any respiratory complications and oxygen saturation remained maintained. On 7th day RT-PCR was found to be negative. Plethora of literature is available on anti-viral and immunomodulatory efficacies of Ayurveda herbs based on in vitro studies. Such efficacies can be replicated at patient's level if supported with wisdom of Ayurveda epistemology. Early diagnosis on RT-PCR and early inception of ayurveda medicine and diet interventions might be crucial element for better recovery.
format Online
Article
Text
id pubmed-9372187
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93721872022-08-12 COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation Dilip Pandkar, Prasad Deshmukh, Santosh Raosaheb Sachdeva, Vinay J Ayurveda Integr Med Case Report ‘Renaissance took place in Chaos and plague’. It was COVID-19 pandemic, when world realized ayurveda co-interventions are praiseworthy even in acute, infective and fatal conditions like COVID-19. We report perhaps first case of COVID-19 patient with cancer managed with poly-herbal ayurvedic formulation and integrated approach. In the first wave of COVID-19 (June 2020), a 47 year old male with history of Chronic kidney disease and active B Cell Lymphoma complained of fever, malaise, cattarah and ageusia. He was found positive on RT-PCR which was done promptly and was later treated in home quarantine with antipyretics, Vitamin C and Madhav rasayan a polyherbal preparation containing Piper longum, Glycyrrhiza glabra, Eclipta alba, Achyranthes aspera, Embelia ribes and Aloe vera designed to modulate host response. It was challenging to treat a patient with cancer with immunocompromised status as he had recently finished his chemotherapy cycle (R–CHOP regimen). Patient well tolerated the intervention and recovered symptomatically. He did not developed any respiratory complications and oxygen saturation remained maintained. On 7th day RT-PCR was found to be negative. Plethora of literature is available on anti-viral and immunomodulatory efficacies of Ayurveda herbs based on in vitro studies. Such efficacies can be replicated at patient's level if supported with wisdom of Ayurveda epistemology. Early diagnosis on RT-PCR and early inception of ayurveda medicine and diet interventions might be crucial element for better recovery. Elsevier 2022 2022-08-12 /pmc/articles/PMC9372187/ /pubmed/35975131 http://dx.doi.org/10.1016/j.jaim.2022.100632 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Dilip Pandkar, Prasad
Deshmukh, Santosh Raosaheb
Sachdeva, Vinay
COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation
title COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation
title_full COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation
title_fullStr COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation
title_full_unstemmed COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation
title_short COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation
title_sort covid-19 patient with b cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372187/
https://www.ncbi.nlm.nih.gov/pubmed/35975131
http://dx.doi.org/10.1016/j.jaim.2022.100632
work_keys_str_mv AT dilippandkarprasad covid19patientwithbcelllymphomacomorbiditymanagedwithcoadministrationofayurvedicformulation
AT deshmukhsantoshraosaheb covid19patientwithbcelllymphomacomorbiditymanagedwithcoadministrationofayurvedicformulation
AT sachdevavinay covid19patientwithbcelllymphomacomorbiditymanagedwithcoadministrationofayurvedicformulation